TCG Crossover Management »

Dianthus Therapeutics shares owned by TCG Crossover Management

Quarter-by-quarter ownership of Dianthus Therapeutics (DNTH) shares owned by TCG Crossover Management from 13F filings

Historical chart of TCG Crossover Management investment in Dianthus Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Dianthus Therapeutics held by TCG Crossover Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Dianthus Therapeutics by TCG Crossover Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $66M 1.7M 39.35
2025-06-30 $28M 1.5M 18.63
2025-03-31 $27M 1.5M 18.14
2024-12-31 $33M 1.5M 21.80

More positions owned by TCG Crossover Management

Abivax Sa American Depositary Shares Adrs (ABVX)
Cg Oncology Comm (CGON)
Cogent Biosciences Comm (COGT)
Amylyx Pharmaceuticals Comm (AMLX)
Centessa Pharmaceuticals Adrs (CNTA)
Tango Therapeutics Comm (TNGX)
Ocular Therapeutix Comm (OCUL)
Dianthus Therapeutics Comm (DNTH)
Tourmaline Bio Comm (TRML)
Dyne Therapeutics Comm (DYN)
Agios Pharmaceuticals Comm (AGIO)
Eyepoint Pharmaceuticals Comm (EYPT)
Fulcrum Therapeutics Comm (FULC)
Savara Comm (SVRA)
Rapt Therapeutics Comm (RAPT)

View all positions for TCG Crossover Management

Top funds holding Dianthus Therapeutics

FMR
Fairmount Funds Management
Avidity Partners Management
RA Capital Management
Wellington Management Company
Octagon Capital Advisors
Point72 Asset Management
TCG Crossover Management
Vanguard Group
BlackRock
Bain Capital Life Sciences Investors
Vestal Point Capital
Citadel Advisors
VR Adviser
Alliancebernstein

View all funds holding Dianthus Therapeutics